InnoCare Pharma (HKG:9969) said it secured regulatory approval to begin a phase 3 clinical trial of orelabrutinib in systemic lupus erythematosus, according to a Hong Kong bourse filing Sunday.
Shares of the pharmaceutical company fell nearly 2% in late morning trade Monday.
The company plans to recruit the first patient in the study during the first quarter of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments